Latest market price
126.59
+0.07+0.06%
ITGRQT71Integer Holdings Corporation·NYSE
126.59+0.06%
TA
Loading chart...
Signal & projected range
Earnings big miss — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index—P/E42.48EPS (ttm)2.98Insider Own2.60%Shs Outstand34.00MPerf Week0.04%
Market Cap4.30BForward P/E18.45EPS next Y6.86Insider Trans-4.63%Shs Float29.04MPerf Month0.13%
Enterprise Value5.63BPEG2.97EPS next Q1.78Short Float11.19%Perf Quarter1.72%
Income105.00MP/S2.36EPS this Y-2.90%Short Ratio3.05Perf Half Y50.65%
Sales1.82BP/B2.49EPS next Y11.50%ROA3.06%Short Interest3.25MPerf YTD61.41%
Book/sh50.77P/C—EPS next 5Y11.63%ROE6.02%52W High126.83 -0.19%Perf Year93.86%
Cash/sh0.41P/FCF52.48EPS past 3/5Y13.82% 4.40%ROIC4.47%52W Low62.00 104.18%Perf 3Y82.35%
Dividend Est.—EV/EBITDA19.60Sales past 3/5Y11.52% 11.46%Gross Margin23.58%Volatility0.14% 0.12%Perf 5Y38.18%
Dividend TTM—EV/Sales3.08EPS Y/Y TTM24.69%Oper. Margin8.17%ATR (14)0.22Perf 10Y556.25%
Dividend Ex-Date—Quick Ratio2.60Sales Y/Y TTM0.00%Profit Margin5.68%RSI (14)62.20Recom2.50
Dividend Gr. 3/5Y—Current Ratio3.98EPS Q/Q-25.14%SMA20-0.01%Beta0.60Target Price118.25
Payout0.00%Debt/Eq0.77Sales Q/Q-3.64%SMA500.31%Rel Volume0.63Prev Close126.52
Employees11,000LT Debt/Eq0.77EarningsFeb 18SMA20025.57%Avg Volume909.81KPrice126.59
IPO DateSep 29, 2000Option/ShortYes / YesEPS/Sales Surpr.-20.31% -1.59%Net Debt/EBITDA4.61Volume571,699Change0.06%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-14-26DowngradeBenchmarkBuy → Hold
Aug-04-26DowngradeFreedom Capital MarketsBuy → Hold
Aug-04-26DowngradeTruist SecuritiesBuy → Hold$127
Aug-04-26DowngradeOppenheimerOutperform → Perform
Aug-03-26ReiteratedPiper SandlerOverweight$82 → $127
Aug-03-26DowngradeKeybancOverweight → Sector Weight
Jul-21-26ReiteratedKeyBancOverweight$133 → $104
Jul-16-26ReiteratedTruist SecuritiesBuy$95 → $110
May-13-26UpgradeOppenheimerPerform → Outperform$115
Feb-23-26ReiteratedRaymond JamesOutperform$95 → $101
Latest News· Times ET
Oct-29-26
Oct-22-26
Oct-21-26
Oct-15-26
Oct-13-26
Oct-12-26
Oct-07-26
Oct-06-26
Oct-02-26
Sep-30-26
Sep-29-26
Company

Integer Holdings Corporation functions as a global leader in outsourced medical device manufacturing, maintaining operations across the United States, Puerto Rico, Costa Rica, and other international regions. The company organizes its business into two primary divisions: Medical and Non-Medical. Within its Medical segment, Integer delivers a broad array of devices and components essential for numerous advanced medical procedures. These solutions cater to areas such as interventional cardiology, structural heart conditions, heart failure management, peripheral and neurovascular interventions, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology. Their extensive product portfolio includes cardiac rhythm management devices like implantable pacemakers, defibrillators, cardiac monitors, leads, and heart failure therapies. They also produce neuromodulation devices, such as implantable spinal cord stimulators, alongside critical components like non-rechargeable batteries, feedthroughs, device enclosures, precision-machined parts, and lead sub-assemblies. Furthermore, Integer provides rechargeable battery systems and chargers. A comprehensive range of surgical instruments and components is also offered for arthroscopic, laparoscopic, and general surgery, encompassing items like harmonic scalpels, various blades and shavers, radio frequency and biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment parts, and phacoemulsification needles. Orthopedic offerings comprise specialized instruments for hip, knee, and spine surgeries, including reamers and chisels, among other general medical technologies. The Non-Medical segment concentrates on developing customized battery power and management systems, along with specialized battery solutions, designed for the energy, military, and environmental sectors. Integer primarily collaborates with multinational original equipment manufacturers (OEMs) and their affiliated subsidiaries, supporting their requirements across diverse markets, including cardiac, neuromodulation, orthopedics, vascular, advanced surgical, and portable medical applications. Established in 1970, Integer Holdings Corporation is headquartered in Plano, Texas.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,8251,8461,7171,556—————
Cost of Goods Sold Incl. D&A1,3941,4211,2551,144—————
Gross Profit431426461412—————
Selling, General and Administrative Excl. Other211163184171—————
Research and Development51465362—————
Other Operating Expense1881615—————
Operating Income149209208163—————
Interest Expense39425653—————
Unusual Expense
—————————
Non-Operating Income (Expense)-2-42-4-5—————
Net Income Before Taxes108125148105—————
Income Taxes5232716—————
Consolidated Net Income10510312091—————
Net Income From Continuing Operations10510312189—————
Net Income10510312091—————
EPS (Recurring)3.002.963.602.72—————
EPS (Basic, Before Extraordinaries)3.002.963.602.72—————
EPS (Diluted)2.982.893.402.69—————
EBITDA287298334278—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio42.4827.1438.9836.83—————
Price To Sales Ratio2.361.492.622.10—————
Gross Margin23.6223.0826.8526.48—————
Operating Margin8.1611.3212.1110.48—————
Net Margin5.755.586.995.85—————
Shares Outstanding34353433—————
Market Capitalization4,3042,7454,5063,270—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$136.26$115.65$95.03$74.42$53.81● Close Price0.00M1.29M2.58M3.88M5.17MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Khales PaymanPresident & CEOOct 24 '26Option Exercise0.002,514064,368Oct 26
Thor Kirk KChief Human Resources OfficerSep 15 '26Sale126.2311,7671,485,2957,153Sep 16
Thor Kirk KChief Human Resources OfficerSep 14 '26Sale126.2519,7732,496,43018,920Sep 16
Senn AndrewPresident, Growth & InnovationSep 08 '26Sale126.309,4081,188,2305,405Sep 10
Thor Kirk KChief Human Resources OfficerJun 30 '26Option Exercise0.006,120041,102Jul 01
Stephens JimPresident, CRM & NeuroMay 15 '26Option Exercise0.001,96306,331May 19
Smith DironEVP, Chief Financial OfficerMay 08 '26Option Exercise0.002,063013,422May 12
Harris John AEVP, Global Ops and ManufacturMar 31 '26Option Exercise0.003,837010,499Apr 02
Carr TerenceEVP, Qlty & Regulatory AffairsMar 24 '26Option Exercise0.001,35001,350Mar 25
Blackwood Lindsay K.SVP, Gen Counsel & SecretaryMar 24 '26Option Exercise0.003,48303,483Mar 25
Thomas Tommy PVP, Corporate ControllerMar 13 '26Sale85.0082570,1254,381Mar 17
Khales PaymanPresident & CEOFeb 24 '26Option Exercise0.0043,060078,799Feb 24
Senn AndrewSVP, Strategy and Business DevJan 20 '26Option Exercise0.002,224012,625Jan 21
Thomas Tommy PVP, Corporate ControllerJan 20 '26Option Exercise0.0033704,391Jan 21
Khales PaymanPresident & CEOJan 20 '26Option Exercise0.001,348026,434Jan 21
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.